atbtherapeutics

ATB Therapeutics is a Belgian preclinical-stage biopharmaceutical company founded in 2018, headquartered in Aye, Luxembourg, with an additional location in Ghent.

The company specializes in developing a novel class of therapies known as "atbodies," which are antibody-toxin-bioengineered treatments aimed at addressing hard-to-treat cancers and autoimmune diseases. The core technology of ATB Therapeutics involves rapidly produced bifunctional antibodies that combine multiple targeting and killing domains in a single molecule. This innovative approach enhances potency and stability while avoiding major cancer cell resistance pathways. The company is currently advancing its pipeline, with programs targeting non-Hodgkin lymphoma and autoimmune conditions, and plans to initiate clinical trials in the coming years. ATB Therapeutics collaborates with iBio CDMO for large-scale production of its therapies, focusing on the Belgian market with aspirations for global reach.